晚期NSCLC患者胸腔积液中IL-6水平及其与EGFR-TKIs治疗疗效的相关性  

Detection of IL-6 Levels in Pleural Effusion in Patients with Advanced NSCLC and Its Correlation with the Efficacy of EGFR-TKIs Therapy

作　　者：马慧利[1] 任中海[1] 梅馨月 MA Huili;REN Zhonghai;MEI Xinyue(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2022年第12期2012-2015,共4页The Practical Journal of Cancer

摘　　要：目的研究晚期非小细胞肺癌(NSCLC)患者胸腔积液中白细胞介素-6(IL-6)水平及其与表皮生长因子酪氨酸激酶抑制剂(EGFR-TKIs)治疗疗效的相关性。方法选取75例NSCLC患者进行研究,应用流式荧光法对所有患者胸腔积液中IL-6水平进行检测,根据患者5年生存状态绘制受试者工作特征(ROC)曲线,确定其胸腔积液IL-6的最佳截断值,并依据该截断值将患者分为升高组(n=20)和无变化组(n=55),2组均应用EGFR-TKIs治疗。观察并比较2组临床治疗效果,采用Spearman秩相关分析法分析胸腔积液中IL-6水平与EGFR-TKIs治疗疗效的相关性。结果治疗后,IL-6水平升高组患者客观缓解率为40.00%,显著低于IL-6水平无变化组患者(70.91%),差异具有统计学意义(P<0.05)。胸腔积液IL-6水平与EGFR-TKIs治疗疗效呈负相关(P<0.05)。升高组的无复发生存期(RFS)、总生存期(OS)均显著短于无变化组,差异有统计学意义(P<0.05)。结论晚期NSCLC患者胸腔积液中IL-6水平与EGFR-TKIs治疗疗效呈负相关,且与生存预后相关,可将其作为预测EGFR-TKIs治疗疗效的有效指标。Objective To study the detection of interleukin-6(IL-6)levels in pleural effusion in patients with advanced non-small cell lung cancer(NSCLC)and its correlation with the therapeutic efficacy of epidermal growth factor tyrosine kinase inhibitors(EGFR-TKIs).Methods 75 patients with NSCLC were selected,the level of IL-6 in pleural effusion was detected by flow fluorometry in all patients,and the receiver operating characteristic(ROC)curve was drawn according to the 5-year survival status of the patients to determine the optimal cut-off value of IL-6 in pleural effusion,and according to the cut-off value,the patients were divided into the elevated group(n=20)and the unchanged group(n=55),both groups were treated with EGFR-TKIs.The clinical therapeutic effects of the 2 groups were observed and compared,and the Spearman rank correlation analysis method was used to analyze the correlation between the level of IL-6 in pleural effusion and the therapeutic effect of EGFR-TKIs.Results After treatment,the objective remission rate of patients in the elevated IL-6 level group was 40.00%,which was significantly lower than that of the patients in the unchanged IL-6 level group(70.91%)(P<0.05).The level of IL-6 in pleural effusion was negatively correlated with the therapeutic effect of EGFR TKIs(P<0.05).The recurrence-free survival(RFS)and overall survival(OS)of the elevated group were significantly shorter than those of the unchanged group,and statistically significant(P<0.05).Conclusion The level of IL-6 in pleural effusion of patients with advanced NSCLC is negatively related to the therapeutic effect of EGFR TKIs,and is related to the survival prognosis,which can be used as an effective indicator to predict the efficacy of EGFR-TKIs treatment.

关 键 词：晚期非小细胞肺癌 胸腔积液 白介素-6 表皮生长因子酪氨酸激酶抑制剂 相关性 

分 类 号：R734.2[医药卫生—肿瘤]